BrandWikiReturn

Olanzapine

Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. It is also sometimes used off-label in cancer patients for treatment of chemotherapy-induced nausea and vomiting[8] and as an appetite stimulant.[9] For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

Common side effects include feeling tired, dizziness, constipation, dry mouth, and restlessness. Other side effects include low blood pressure with standing, allergic reactions, neuroleptic malignant syndrome, diabetes mellitus, seizures, and tardive dyskinesia. In older people with dementia, its use increases the risk of death. Use in the later part of pregnancy may result in a movement disorder in the baby for some time after birth. Although its mechanism of action is not entirely clear, it is known to block dopamine and serotonin receptors.

Olanzapine was patented in 1991 and approved for medical use in the United States in 1996.[10][11] It is available as a generic medication.[10] In 2023, it was the 167th most commonly prescribed medication in the United States, with more than 3million prescriptions.[12][13] It is on the World Health Organization's List of Essential Medicines.[14]

Medical uses

It is approved by the FDA for the following indications:

In the United Kingdom and Australia, it is approved for schizophrenia, moderate to severe manic episodes, alone, or in combination with lithium or valproate and the short-term treatment of acute manic episodes associated with bipolar I disorder.[19]

Olanzapine is also used off-label for the treatment of chemotherapy-induced nausea and vomiting.[8]

  • schizophrenia.
  • acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder.
  • adjunct to lithium or valproate in the treatment of manic or mixed episodes associated with bipolar I disorder.
  • combination olanzapine/fluoxetine (Symbyax) for the treatment of depressive episodes of bipolar I disorder and for treatment-resistant depression.[15][16][17][2]
  • combination olanzapine/samidorphan (Lybalvi) for the treatment of schizophrenia and bipolar I disorder. Lybalvi suppresses the metabolic side effect of olanzapine. More precisely, olanzapine produces weight gain of about 9 kg (20 pounds) in the short-term, which typically increases to around 23–45 kg (50–100 pounds) following long-term use. In contrast, Lybalvi only triggers roughly 5 kg (11 pounds) before subsiding.[18]

Schizophrenia

The first-line psychiatric treatment for schizophrenia is antipsychotic medication.[20] Olanzapine appears to be effective in reducing symptoms of schizophrenia, treating acute exacerbations, and treating early-onset schizophrenia.[21][22][23][24] The usefulness of maintenance therapy, however, is difficult to determine, as more than half of people in trials quit before the 6-week completion date.[25] Treatment with olanzapine (like clozapine) may result in increased weight gain and increased glucose and cholesterol levels when compared to most other second-generation antipsychotic drugs used to treat schizophrenia.[22][26]

Bipolar disorder

Olanzapine is recommended by the National Institute for Health and Care Excellence as a first-line therapy for the treatment of acute mania in bipolar disorder. Other recommended first-line treatments are aripiprazole, haloperidol, quetiapine, and risperidone.[27] It is recommended in combination with fluoxetine as a first-line therapy for acute bipolar depression, and as a second-line treatment by itself for the maintenance treatment of bipolar disorder.[28]

The Network for Mood and Anxiety Treatments recommends olanzapine as a first-line maintenance treatment for bipolar disorder and the combination of olanzapine with fluoxetine as a second-line treatment for bipolar depression.[29]

A review on the efficacy of olanzapine as maintenance therapy in people with bipolar disorder was published in 2006.[30] A 2014 meta-analysis concluded that olanzapine with fluoxetine was the most effective among nine treatments for bipolar depression included in the analysis.[31]

Specific populations

Pregnancy and lactation

Olanzapine is associated with the highest placental exposure of any atypical antipsychotic.[32] Despite this, the available evidence suggests it is safe during pregnancy, although the evidence is insufficiently strong to say anything with a high degree of confidence.[32] Olanzapine is associated with weight gain, which according to recent studies, may put olanzapine-treated patients' offspring at a heightened risk for neural tube defects (e.g. spina bifida).[33][34] Breastfeeding in women taking olanzapine is advised against because olanzapine is secreted in breast milk, with one study finding that the exposure to the infant is about 1.8% that of the mother.

Elderly

Citing an increased risk of stroke, in 2004, the Committee on the Safety of Medicines in the UK issued a warning that olanzapine and risperidone, both atypical antipsychotic medications, should not be given to elderly patients with dementia. In the U.S., olanzapine comes with a black box warning for increased risk of death in elderly patients. It is not approved for use in patients with dementia-related psychosis.[35] A BBC investigation in June 2008 found that this advice was being widely ignored by British doctors.[36] Evidence suggested that the elderly are more likely to experience weight gain on olanzapine compared to aripiprazole and risperidone.[37]

Pregnancy and lactation

Olanzapine is associated with the highest placental exposure of any atypical antipsychotic.[32] Despite this, the available evidence suggests it is safe during pregnancy, although the evidence is insufficiently strong to say anything with a high degree of confidence.[32] Olanzapine is associated with weight gain, which according to recent studies, may put olanzapine-treated patients' offspring at a heightened risk for neural tube defects (e.g. spina bifida).[33][34] Breastfeeding in women taking olanzapine is advised against because olanzapine is secreted in breast milk, with one study finding that the exposure to the infant is about 1.8% that of the mother.

Elderly

Citing an increased risk of stroke, in 2004, the Committee on the Safety of Medicines in the UK issued a warning that olanzapine and risperidone, both atypical antipsychotic medications, should not be given to elderly patients with dementia. In the U.S., olanzapine comes with a black box warning for increased risk of death in elderly patients. It is not approved for use in patients with dementia-related psychosis.[35] A BBC investigation in June 2008 found that this advice was being widely ignored by British doctors.[36] Evidence suggested that the elderly are more likely to experience weight gain on olanzapine compared to aripiprazole and risperidone.[37]

Adverse effects

The principal side effect of olanzapine is weight gain, which may be profound in some cases and/or associated with derangement in blood-lipid and blood-sugar profiles (see section metabolic effects). A 2013 meta-analysis of the efficacy and tolerance of 15 antipsychotic drugs (APDs) found that it had the highest propensity for causing weight gain out of the 15 APDs compared with an SMD of 0.74.[21] Extrapyramidal side effects, although potentially serious, are infrequent to rare from olanzapine,[38] but may include tremors and muscle rigidity.

Although olanzapine causes an early dose-related rise in prolactin, this is less frequent and less marked than that seen with haloperidol, and is usually transient. A rise in prolactin is seen in about half of patients on olanzapine compared to over 90% of those taking risperidone, and enduring increases were less frequent in those taking olanzapine.[39]

It is not recommended to be used by IM injection in acute myocardial infarction, bradycardia, recent heart surgery, severe low blood pressure, sick sinus syndrome, and unstable angina.[40]

Several patient groups are at a heightened risk of side effects from olanzapine and antipsychotics in general. Olanzapine may produce nontrivial high blood sugar in people with diabetes mellitus. Likewise, the elderly are at a greater risk of falls and accidental injury. Young males appear to be at heightened risk of dystonic reactions, although these are relatively rare with olanzapine. Most antipsychotics, including olanzapine, may disrupt the body's natural thermoregulatory systems, thus permitting excursions to dangerous levels when certain situations (exposure to heat, strenuous exercise) occur.[41][42][43][2][44]

Other side effects possibly include galactorrhea, amenorrhea, gynecomastia, and erectile dysfunction (impotence).[45]

Metabolic effects

The US Food and Drug Administration (FDA) requires atypical antipsychotics to include a warning about the risk of developing hyperglycemia and diabetes, both of which are factors in the metabolic syndrome. These effects may be related to the drugs' ability to induce weight gain, although some reports have been made of metabolic changes in the absence of weight gain.[46][47] Studies have indicated that olanzapine carries a greater risk of causing and exacerbating diabetes than another commonly prescribed atypical antipsychotic, risperidone. Of all the atypical antipsychotics, olanzapine is the most likely to induce significant weight gain based on various measures.[48][49][50][51][52] The effect is dose dependent in humans[53] and animal models of olanzapine-induced metabolic side effects. There are some case reports of olanzapine-induced diabetic ketoacidosis.[54] Olanzapine may decrease insulin sensitivity,[55][56] though one 3-week study seems to refute this.[57] It may also increase triglyceride levels.[49]

Despite weight gain, a large multicenter, randomized National Institute of Mental Health study found that olanzapine was better at controlling symptoms because patients were more likely to remain on olanzapine than the other drugs.[58] One small, open-label, nonrandomized study suggests that taking olanzapine by orally dissolving tablets may induce less weight gain,[59] but this has not been substantiated in a blinded experimental setting.

Post-injection delirium/sedation syndrome

Postinjection delirium/sedation syndrome (PDSS) is a rare syndrome that is specific to the long-acting injectable formulation of olanzapine, olanzapine pamoate.[60] The incidence of PDSS with olanzapine pamoate is estimated to be 0.07% of administrations, and is unique among other second-generation, long-acting antipsychotics (e.g. paliperidone palmitate), which do not appear to carry the same risk.[60] PDSS is characterized by symptoms of delirium (e.g. confusion, difficulty speaking, and uncoordinated movements) and sedation.[60] Most people with PDSS exhibit both delirium and sedation (83%).[60] Although less specific to PDSS, a majority of cases (67%) involved a feeling of general discomfort.[60] PDSS may occur due to accidental injection and absorption of olanzapine pamoate into the bloodstream, where it can act more rapidly, as opposed to slowly distributing out from muscle tissue.[60] Using the proper, intramuscular-injection technique for olanzapine pamoate helps to decrease the risk of PDSS, though it does not eliminate it entirely.[60] This is why the FDA advises that people who are injected with olanzapine pamoate be watched for 3 hours after administration, in the event that PDSS occurs.[60]

Animal toxicology

Olanzapine has demonstrated carcinogenic effects in multiple studies when exposed chronically to female mice and rats, but not male mice and rats. The tumors found were in either the liver or mammary glands of the animals.[61]

Discontinuation

The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[62] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[63] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[63] Less commonly, vertigo, numbness, or muscle pains may occur.[63] Symptoms generally resolve after a short time.[63]

Tentative evidence indicates that discontinuation of antipsychotics can result in psychosis, as a temporary withdrawal symptom.[64] It may also result in reoccurrence of the condition that is being treated.[65] Rarely, tardive dyskinesia can occur when the medication is stopped.[63]

Overdose

Symptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness, and coma. Death has been reported after an acute overdose of 450 mg, but also survival after an acute overdose of 2000 mg.[66] Fatalities generally have occurred with olanzapine plasma concentrations greater than 1000 ng/mL post mortem, with concentrations up to 5200 ng/mL recorded (though this might represent confounding by dead tissue, which may release olanzapine into the blood upon death). No specific antidote for olanzapine overdose is known, and even physicians are recommended to call a certified poison control center for information on the treatment of such a case.[66] Olanzapine is considered moderately toxic in overdose, more toxic than quetiapine, aripiprazole, and the SSRIs, and less toxic than the monoamine oxidase inhibitors and tricyclic antidepressants.[32]

Interactions

Drugs or agents that increase the activity of the enzyme CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of olanzapine; conversely, drugs that inhibit CYP1A2 activity (examples: ciprofloxacin, fluvoxamine) may reduce olanzapine clearance.[67] Carbamazepine, a known enzyme inducer, has decreased the concentration/dose ratio of olanzapine by 33% compared to olanzapine alone. Another enzyme inducer, ritonavir, has also been shown to decrease the body's exposure to olanzapine, due to its induction of the enzymes CYP1A2 and uridine 5'-diphospho-glucuronosyltransferase (UGT). Probenecid increases the total exposure (area under the curve) and maximum plasma concentration of olanzapine. Although olanzapine's metabolism includes the minor metabolic pathway of CYP2D6, the presence of the CYP2D6 inhibitor fluoxetine does not have a clinically significant effect on olanzapine's clearance.

Olanzapine has been used as a hallucinogen antidote to block the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).[68][69]

Pharmacology

Pharmacodynamics

Olanzapine was first discovered while searching for a chemical analog of clozapine that would not require hematological monitoring. Investigation on a series of thiophene isosteres on 1 of the phenyl rings in clozapine, a thienobenzodiazepine analog (olanzapine) was discovered.[88]

Olanzapine has a higher affinity for 5-HT2A serotonin receptors than D2 dopamine receptors, which is a common property of most atypical antipsychotics, aside from the benzamide antipsychotics such as amisulpride along with the nonbenzamides aripiprazole, brexpiprazole, blonanserin, cariprazine, melperone, and perospirone.

In one study D2 receptor occupancy was 60% with low-dose olanzapine (5 mg/day) and occupancy with high dose at 83% (20 mg/day).[89] In the usual clinical dose range of 10–20 mg/day, D2 receptor occupancy varied from 71% to 80%.[90]

Olanzapine occupancy at 5-HT2A receptor are high at all doses (5 mg to 20 mg). It is reported that 5 mg dose of olanzapine produced a mean occupancy of 85% at 5 mg, 88% at 10 mg, and 93% at 20 mg dose.[91]

Olanzapine had the highest affinity of any second-generation antipsychotic towards the P-glycoprotein in one in vitro study.[92] P-glycoprotein transports a myriad of drugs across a number of different biological membranes (found in numerous body systems) including the blood–brain barrier (a semipermeable membrane that filters the contents of blood prior to it reaching the brain); P-GP inhibition could mean that less brain exposure to olanzapine results from this interaction with the P-glycoprotein.[93] A relatively large quantity of commonly encountered foods and medications inhibit P-GP, and pharmaceuticals fairly commonly are either substrates of P-GP or inhibit its action; both substrates and inhibitors of P-GP effectively increase the permeability of the blood-brain barrier to P-GP substrates and subsequently increase the central activity of the substrate, while reducing the local effects on the GI tract. The mediation of olanzapine in the central nervous system by P-GP means that any other substance or drug that interacts with P-GP increases the risk for toxic accumulations of both olanzapine and the other drug.[94]

Olanzapine is a potent antagonist of the muscarinic M3 receptor,[95] which may underlie its diabetogenic side effects.[96][97] Additionally, it also exhibits a relatively low affinity for serotonin 5-HT1, GABAA, β-adrenergic receptors, and benzodiazepine binding sites.[38][98]

Although antagonistic effects of olanzapine at 5-HT2C alone are not associated with weight gain, olanzapine antagonism at histaminergic H1, muscarinic M3 and dopamine D2 receptors have been associated with weight gain and appetite stimulation.[88][99][100][101]

The mode of action of olanzapine's antipsychotic activity is unknown. It may involve antagonism of dopamine and serotonin receptors. Antagonism of dopamine receptors is associated with extrapyramidal effects such as tardive dyskinesia (TD), and with therapeutic effects. Antagonism of muscarinic acetylcholine receptors is associated with anticholinergic side effects such as dry mouth and constipation; in addition, it may suppress or reduce the emergence of extrapyramidal effects for the duration of treatment, but it offers no protection against the development of TD. In common with other second-generation (atypical) antipsychotics, olanzapine poses a relatively low risk of extrapyramidal side effects including TD, due to its higher affinity for the 5HT2A receptor over the D2 receptor.[102]

Antagonizing H1 histamine receptors causes sedation.

Pharmacokinetics

Metabolism

Olanzapine is metabolized by the cytochrome P450 (CYP) system; principally by isozyme 1A2 (CYP1A2) and to a lesser extent by CYP2D6. By these mechanisms, more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect.[38] Clearance of olanzapine appears to vary by sex; women have roughly 25% lower clearance than men.[103] Clearance of olanzapine also varies by race; in self-identified African Americans or Blacks, olanzapine's clearance was 26% higher.[103] A difference in the clearance is not apparent between individuals identifying as Caucasian, Chinese, or Japanese.[103] Routine, pharmacokinetic monitoring of olanzapine plasma levels is generally unwarranted, though unusual circumstances (e.g. the presence of drug-drug interactions) or a desire to determine if patients are taking their medicine may prompt its use.[103]

Chemistry

Olanzapine is unusual in having four well-characterised crystalline polymorphs and many hydrated forms.[104]

Metabolism

Olanzapine is metabolized by the cytochrome P450 (CYP) system; principally by isozyme 1A2 (CYP1A2) and to a lesser extent by CYP2D6. By these mechanisms, more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect.[38] Clearance of olanzapine appears to vary by sex; women have roughly 25% lower clearance than men.[103] Clearance of olanzapine also varies by race; in self-identified African Americans or Blacks, olanzapine's clearance was 26% higher.[103] A difference in the clearance is not apparent between individuals identifying as Caucasian, Chinese, or Japanese.[103] Routine, pharmacokinetic monitoring of olanzapine plasma levels is generally unwarranted, though unusual circumstances (e.g. the presence of drug-drug interactions) or a desire to determine if patients are taking their medicine may prompt its use.[103]

Chemistry

Olanzapine is unusual in having four well-characterised crystalline polymorphs and many hydrated forms.[104]

Chemical synthesis

The preparation of olanzapine was first disclosed in a series of patents from Eli Lilly & Co. in the 1990s. In the final two steps, 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile was reduced with stannous chloride in ethanol to give the substituted thienobenzodiazepine ring system, and this was treated with methylpiperazine in a mixture of dimethyl sulfoxide and toluene as solvent to produce the drug.[105]

  • Olanzapine synthesis.svg

Society and culture

Legal status

Olanzapine is approved by the US FDA for:

The drug became generic in 2011. Sales of Zyprexa in 2008 were $2.2 billion in the US and $4.7 billion worldwide.[113]

  • Treatment—in combination with fluoxetine—of depressive episodes associated with bipolar disorder (December 2003).[106]
  • Long-term treatment of bipolar I disorder (January 2004).[107][108]
  • Long-term treatment—in combination with fluoxetine—of resistant depression (March 2009)[109]
  • Oral formulation: acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder (monotherapy and in combination with lithium or sodium valproate)
  • Intramuscular formulation: acute agitation associated with schizophrenia and bipolar I mania in adults
  • Oral formulation combined with fluoxetine: treatment of acute depressive episodes associated with bipolar I disorder in adults, or treatment of acute, resistant depression in adults[110]
  • Treatment of the manifestations of psychotic disorders (September 1996[111] – March 2000).[112]
  • Short-term treatment of acute manic episodes associated with bipolar I disorder (March 2000)[112]
  • Short-term treatment of schizophrenia instead of the management of the manifestations of psychotic disorders (March 2000)[112]
  • Maintaining treatment response in schizophrenic patients who had been stable for about eight weeks and were then followed for a period of up to eight months (November 2000)[112]

Controversy and litigation

Eli Lilly has faced many lawsuits from people who claimed they developed diabetes or other diseases after taking Zyprexa, as well as by various governmental entities, insurance companies, and others. Lilly produced a large number of documents as part of the discovery phase of this litigation, which started in 2004; the documents were ruled to be confidential by a judge and placed under seal, and later themselves became the subject of litigation.

In 2006, Lilly paid $700 million to settle around 8,000 of these lawsuits,[114] and in early 2007, Lilly settled around 18,000 suits for $500 million, which brought the total Lilly had paid to settle suits related to the drug to $1.2 billion.[115]

A December 2006 New York Times article based on leaked company documents concluded that the company had engaged in a deliberate effort to downplay olanzapine's side effects.[115][116] The company denied these allegations and stated that the article had been based on cherry-picked documents.[115] The documents were provided to the Times by Jim Gottstein, a lawyer who represented mentally ill patients, who obtained them from a doctor, David Egilman, who was serving as an expert consultant on the case. After the documents were leaked to online peer-to-peer, file-sharing networks by Will Hall and others in the psychiatric survivors movement, who obtained copies,[117] in 2007 Lilly filed a protection order to stop the dissemination of some of the documents, which Judge Jack B. Weinstein of the Brooklyn Federal District Court granted. Judge Weinstein also criticized the New York Times reporter, Gottstein, and Egilman in the ruling. The Times of London also received the documents and reported that as early as 1998, Lilly considered the risk of drug-induced obesity to be a "top threat" to Zyprexa sales.[118] On 9 October 2000, senior Lilly research physician Robert Baker noted that an academic advisory board to which he belonged was "quite impressed by the magnitude of weight gain on olanzapine and implications for glucose."[118]

Lilly had threatened Egilman with criminal contempt charges regarding the documents he took and provided to reporters; in September 2007, he agreed to pay Lilly $100,000 in return for the company's agreement to drop the threat of charges.[119]

In September 2008, Judge Weinstein issued an order to make public Lilly's internal documents about the drug in a different suit brought by insurance companies, pension funds, and other payors.[120]

In March 2008, Lilly settled a suit with the state of Alaska,[121] and in October 2008, Lilly agreed to pay $62 million to 32 states and the District of Columbia to settle suits brought under state consumer protection laws.[119]

In 2009, Eli Lilly pleaded guilty to a US federal criminal misdemeanor charge of illegally marketing Zyprexa for off-label use and agreed to pay $1.4 billion. The settlement announcement stated "Eli Lilly admits that between September 1999 and March 31, 2001, the company promoted Zyprexa in elderly populations as a treatment for dementia, including Alzheimer's dementia. Eli Lilly has agreed to pay a $515 million criminal fine and to forfeit an additional $100 million in assets."[122][123]

The outcomes described here, and their legal ramifications, were fueled by motions and appeals that were not resolved until 2010.[124] In 2021, Gottstein summarized this tangle of legal activities, and their impact on the political landscape of psychiatry and antipsychiatry in the US, in The Zyprexa Papers.[125]

Brand names

Olanzapine is generic and available under many brand names worldwide.[126]

Dosage forms

Olanzapine is marketed in many countries, with tablets ranging from 2.5 to 20 mg. Zyprexa (and generic olanzapine) is available as an orally disintegrating "wafer", which rapidly dissolves in saliva. It is also available in 10-mg vials for intramuscular injection.[67]

Research

Olanzapine may be useful in promoting weight gain in underweight adult outpatients with anorexia nervosa. However, no improvement in psychological symptoms was noted.[127] It has also been shown to be helpful in the management of cancer-related anorexia.[9]

Olanzapine has been shown to help address a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and has since been used in the treatment of a range of mood and anxiety disorders.[128] Olanzapine is no less effective than lithium or valproate and more effective than placebo in treating bipolar disorder.[129] It has also been used for Tourette syndrome and stuttering.[130]

Olanzapine has been studied for the treatment of hyperactivity, aggressive behavior, and repetitive behaviors in autism.[131]

Olanzapine is frequently prescribed off-label for the treatment of insomnia, including difficulty falling asleep and staying asleep, even though such use is not recommended.[132] The daytime sedation experienced with olanzapine is generally comparable to quetiapine and lurasidone, which is a frequent complaint in clinical trials. In some cases, the sedation due to olanzapine impaired the ability of people to wake up at a consistent time every day. Some evidence of efficacy for treating insomnia is seen; however, side effects such as dyslipidemia and neutropenia, which may be observed even at low doses, outweigh any potential benefits for insomnia that are not due to an underlying mental health condition, and which can be treated effectively with FDA approved Z-drugs that do not present with the severe cardiometabolic adverse effects of antipsychotics and who present with very little to no potential for addiction compared with benzodiazepines.[133][134][135][136]

Olanzapine has been recommended to be used in antiemetic regimens in people receiving chemotherapy that has a high risk for vomiting.[137]

Olanzapine has been studied as an antiemetic, particularly for the control of chemotherapy-induced nausea and vomiting (CINV).[138]

In general, olanzapine appears to be about as effective as aprepitant for the prevention of CINV, though some concerns remain about its use in this population. For example, concomitant use of metoclopramide or haloperidol increases the risk for extrapyramidal symptoms. Otherwise, olanzapine appears to be fairly well tolerated for this indication, with somnolence being the most common side effect.[139] Olanzapine is more effective than metoclopramide for breakthrough CINV.[140] It is also more effective than placebo when added to a combination of palonosetron, dexamethasone and aprepitant.[141]

Olanzapine has been considered as part of an early psychosis approach for schizophrenia. The Prevention through Risk Identification, Management, and Education study, funded by the National Institute of Mental Health and Eli Lilly, tested the hypothesis that olanzapine might prevent the onset of psychosis in people at very high risk for schizophrenia. The study examined 60 patients with prodromal schizophrenia, who were at an estimated risk of 36–54% of developing schizophrenia within a year and treated half with olanzapine and half with placebo.[142] In this study, patients receiving olanzapine did not have a significantly lower risk of progressing to psychosis (16.1% vs 37.9%). Olanzapine was effective for treating the prodromal symptoms but was associated with significant weight gain.[143]

External links

References

  1. Anvisa. RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial Diário Oficial da União, 31 March 2023, retrieved 16 August 2023^
  2. Zyprexa- olanzapine tablet; Zyprexa Zydis- olanzapine tablet, orally disintegrating; Zyprexa intramuscular- olanzapine injection, powder, for solution DailyMed, 13 December 2023, retrieved 17 October 2024^
  3. Zyprexa EPAR European Medicines Agency (EMA), 27 September 1996, retrieved 27 February 2024^
  4. Zypadhera European Medicines Agency (EMA), 19 November 2008, retrieved 26 October 2024^
  5. Disposition and biotransformation of the antipsychotic agent olanzapine in humans Drug Metabolism and Disposition, January 1997^
  6. Olanzapine. Pharmacokinetic and pharmacodynamic profile Clinical Pharmacokinetics, September 1999^
  7. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response Clinical Pharmacokinetics, 2007^
  8. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients Supportive Care in Cancer, January 2019^
  9. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer Journal of Clinical Oncology, May 2023^
  10. Olanzapine, Olanzapine Pamoate Monograph for Professionals Drugs.com, AHFS, retrieved 24 December 2018^
  11. The Maudsley Prescribing Guidelines in Psychiatry Wiley-Blackwell, 2015^
  12. The Top 300 of 2023 ClinCalc, retrieved 12 August 2025^
  13. Olanzapine Drug Usage Statistics, United States, 2014 - 2023 ClinCalc, retrieved 12 August 2025^
  14. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) World Health Organization, 2023^
  15. Symbyax- olanzapine and fluoxetine hydrochloride capsule DailyMed, 21 April 2020, retrieved 30 September 2020^
  16. StatPearls StatPearls Publishing, 2023, retrieved 20 November 2022^
  17. Olanzapine Indications: FDA-Approved Uses psychopharmacologyinstitute.com, retrieved 20 November 2022^
  18. DailyMed - Lybalvi- olanzapine and samidorphan l-malate tablet, film coated DailyMed^
  19. Olanzapine AN Tablets NPS MedicineWise, May 2018, retrieved 20 November 2022^
  20. Overview www.nice.org.uk, 12 February 2014, retrieved 30 November 2022^
  21. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet, September 2013^
  22. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia CNS Drugs, January 2016^
  23. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis Journal of the American Academy of Child and Adolescent Psychiatry, March 2017^
  24. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia Harvard Review of Psychiatry, 2013^
  25. Olanzapine for schizophrenia The Cochrane Database of Systematic Reviews, April 2005^
  26. Olanzapine versus other atypical antipsychotics for schizophrenia The Cochrane Database of Systematic Reviews, March 2010^
  27. Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder CNS Drugs, February 2014^
  28. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care NICE, 24 September 2014, retrieved 26 July 2016^
  29. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007 Bipolar Disorders, December 2006^
  30. Olanzapine - relapse prevention following mania Journal of Psychopharmacology, March 2006^
  31. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics Pharmacopsychiatry, March 2014^
  32. The Maudsley prescribing guidelines in psychiatry Wiley-Blackwell^
  33. Maternal obesity and risk of neural tube defects: a metaanalysis American Journal of Obstetrics and Gynecology, June 2008^
  34. Maternal obesity, folate intake, and neural tube defects in offspring Birth Defects Research. Part A, Clinical and Molecular Teratology, February 2013^
  35. Important Safety Information for Olanzapine Zyprexa package insert, Eli Lilly & Company, 2007, retrieved 3 December 2007^
  36. Doctors 'ignoring drugs warning' BBC News, 17 June 2008, retrieved 22 June 2008^
  37. Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients SAGE Open Medicine, 8 May 2017^
  38. Lexi-Comp Inc. Lexi-Comp Drug Information Handbook Lexi-Comp Inc., 2010^
  39. Hyperprolactinaemia With Antipsychotics www.medsafe.govt.nz, retrieved 10 October 2022^
  40. Joint Formulary Committee. British National Formulary (online) BMJ Group and Pharmaceutical, retrieved 2 February 2020^
  41. Product Information Olanzapine Sandoz 2.5mg/5mg/7.5mg/10mg/15mg/20mg Film-coated Tablets TGA eBusiness Services, Sandoz Pty Ltd, 8 June 2012, retrieved 26 November 2013^
  42. Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more Medscape Reference, WebMD, retrieved 26 November 2013^
  43. Heat-related side-effects of neurological and non-neurological medication may increase heatwave fatalities European Journal of Neurology, July 2009^
  44. Zyprexa 10 mg coated tablets Summary of Product Characteristics (SmPC) (emc), 2 February 2024, retrieved 26 October 2024^
  45. Olanzapine Monograph for Professionals - Drugs.com Drugs.com, retrieved 24 March 2017^
  46. Olanzapine-induced destabilization of diabetes in the absence of weight gain Acta Psychiatrica Scandinavica, March 2002^
  47. New-onset type-2 diabetes associated with atypical antipsychotic medications Progress in Neuro-Psychopharmacology & Biological Psychiatry, July 2006^
  48. CAFE Study Shows Varying Benefits Among Atypical Antipsychotics Medscape Medical News, WebMD, 25 October 2005, retrieved 3 December 2007^
  49. AstraZeneca Pharmaceuticals. Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomised Double Blind 52 Week Comparison AstraZeneca Clinical Trials, AstraZeneca PLC, 4 April 2006, retrieved 3 December 2007^
  50. Novel antipsychotics: comparison of weight gain liabilities The Journal of Clinical Psychiatry, June 1999^
  51. NIMH study to guide treatment choices for schizophrenia National Institute of Mental Health, 19 September 2005, retrieved 18 December 2006^
  52. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison The American Journal of Psychiatry, July 2007^
  53. Dosing the antipsychotic medication olanzapine The Journal of Clinical Psychiatry, 1997^
  54. Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis Journal of Pharmacy Practice, 2006^
  55. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine Progress in Neuro-Psychopharmacology & Biological Psychiatry, August 2010^
  56. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers Neuropsychopharmacology, June 2008^
  57. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp The Journal of Clinical Endocrinology and Metabolism, December 2003^
  58. Little Difference Found in Schizophrenia Drugs The New York Times, 20 September 2005, retrieved 3 December 2007^
  59. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets Psychopharmacology, September 2004^
  60. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management CNS Drugs, January 2015^
  61. Genotoxic and carcinogenic effects of antipsychotics and antidepressants Toxicology, July 2009^
  62. British National Formulary Royal Pharmaceutical Society of Great Britain, March 2009^
  63. Adverse Syndromes and Psychiatric Drugs: A Clinical Guide OUP Oxford, 2004^
  64. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse Acta Psychiatrica Scandinavica, July 2006^
  65. Adherence to Antipsychotics in Schizophrenia Springer Science & Business Media, 2013^
  66. Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information RxList: The Internet Drug Index, WebMD, 2007, retrieved 3 December 2007^
  67. Olanzapine Prescribing Information Eli Lilly and Company, 19 March 2009, retrieved 6 September 2009^
  68. Trip-killers: a concerning practice associated with psychedelic drug use Emerg Med J, January 2024^
  69. Study Finds Hundreds of Reddit Posts on "Trip-Killers" for Psychedelic Drugs JAMA, February 2024^
  70. PDSP Ki Database Psychoactive Drug Screening Program (PDSP), University of North Carolina at Chapel Hill and the United States National Institute of Mental Health, retrieved 14 August 2017^
  71. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs Neuropsychopharmacology, March 2003^
  72. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies The Pharmacogenomics Journal, 2006^
  73. Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences The Journal of Pharmacology and Experimental Therapeutics, February 1996^
  74. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro Schizophrenia Research, May 1999^
  75. Muscarinic mechanisms of antipsychotic atypicality Progress in Neuro-Psychopharmacology & Biological Psychiatry, October 2003^
  76. Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents Journal of Medicinal Chemistry, March 2005^
  77. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors Molecular Psychiatry, March 1998^
  78. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist The Journal of Pharmacology and Experimental Therapeutics, December 2005^
  79. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacology, March 1996^
  80. Iloperidone binding to human and rat dopamine and 5-HT receptors European Journal of Pharmacology, December 1996^
  81. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand European Journal of Pharmacology, October 1995^
  82. Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one Bioorganic & Medicinal Chemistry, August 2008^
  83. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence Neuropsychopharmacology, February 1998^
  84. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor The Journal of Pharmacology and Experimental Therapeutics, August 1997^
  85. Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology, February 1996^
  86. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium European Journal of Pharmacology, March 2000^
  87. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs European Journal of Pharmacology, August 2002^
  88. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future Neuropsychiatric Disease and Treatment, September 2019^
  89. NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals www.jwatch.org, retrieved 27 November 2022^
  90. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation The American Journal of Psychiatry, July 1998^
  91. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol Neuropsychopharmacology, December 2005^
  92. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein Psychopharmacology, September 2006^
  93. Relationship between P-glycoprotein and second-generation antipsychotics Pharmacogenomics, August 2011^
  94. Drug Transporters: The Final Frontier for Drug Interactions Pharmacy Times, 1 December 2008, retrieved 9 February 2017^
  95. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia Diabetes, May 2005^
  96. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor CNS Drugs, December 2013^
  97. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes Methods and Findings in Experimental and Clinical Pharmacology, June 2005^
  98. olanzapine NCI Drug Dictionary, National Cancer Institute, 2 February 2011^
  99. 5-HT2A and 5-HT2C receptors and their atypical regulation properties Life Sciences, April 2003^
  100. The 5-HT2C receptor and antipsychotic-induced weight gain - mechanisms and genetics Journal of Psychopharmacology, July 2006^
  101. Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain Pharmacogenomics and Personalized Medicine, 18 August 2011^
  102. Foye's Medicinal Chemistry Wolters Kluwer, 2009^
  103. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clinical Pharmacokinetics, July 2011^
  104. Crystal forms in pharmaceutical applications: olanzapine, a gift to crystal chemistry that keeps on giving IUCrJ, November 2020^
  105. Methods of treatment using a thieno-benzodiazepine^
  106. NDA 21–520 Food and Drug Administration, 24 December 2003, retrieved 6 September 2009^
  107. NDA 20-592 / S-019 Food and Drug Administration, 14 January 2004, retrieved 6 September 2009^
  108. Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009 Psychiatric Services, January 2012^
  109. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues Neuropsychiatric Disease and Treatment, 2009^
  110. treatment resistant depression defined as major depressive disorder in adult patients who do not respond to two separate trials of different antidepressants of adequate dose and duration in the current episode^
  111. NDA 20-592 Food and Drug Administration, 6 September 1996, retrieved 6 September 2009^
  112. Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa U.S. Justice Department, 15 January 2009, retrieved 9 July 2012^
  113. Lilly 2008 Annual Report Lilly, 2009, retrieved 6 August 2009^
  114. Mother Wonders if Psychosis Drug Helped Kill Son The New York Times, 4 January 2007, retrieved 21 May 2013^
  115. Lilly Settles With 18,000 Over Zyprexa The New York Times, 5 January 2007^
  116. Eli Lilly Said to Play Down Risk of Top Pill The New York Times, 17 December 2006, retrieved 21 May 2013^
  117. Activist Gagged for Drug Fact Leak in Lily Case Hampshire Daily Gazette, 16 January 2007^
  118. Eli Lilly was concerned by Zyprexa side-effects from 1998 The Times (London), 23 January 2007^
  119. Lilly Said to Be Near $1.4 Billion U.S. Settlement The New York Times, 14 January 2009^
  120. Judge to Unseal Documents on the Eli Lilly Drug Zyprexa The New York Times, 5 September 2008^
  121. Lilly Settles Alaska Suit Over Zyprexa The New York Times, 26 March 2008^
  122. Lilly settles Zyprexa suit for $1.42 billion NBCNews.com, Associated Press, 15 January 2009^
  123. Drug Files Show Maker Promoted Unapproved Use The New York Times, 18 December 2006, retrieved 21 May 2013^
  124. PsychRights. Law Project for Psychiatric Rights: Summary and Links to Relevant Documents in the Zyprexa Scandal PsychRights, 2010, retrieved 26 October 2021^
  125. The Zyreza Papers Samizdat Health Writer's Cooperative 2021, 2021, retrieved 26 October 2021^
  126. Drugs.com international listings for Olanzapine Drugs.com, retrieved 4 August 2015^
  127. Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial The American Journal of Psychiatry, June 2019^
  128. Role of atypical antipsychotics in the treatment of generalized anxiety disorder CNS Drugs, June 2014^
  129. Review of olanzapine in the management of bipolar disorders Neuropsychiatric Disease and Treatment, October 2007^
  130. Genetic and Neurological Factors in Stuttering Stuttering Foundation of America, Winter 2006^
  131. Olanzapine and Autism Research Autism, 19 December 2017, retrieved 9 June 2018^
  132. European guideline for the diagnosis and treatment of insomnia Journal of Sleep Research, December 2017^
  133. Off-label use of atypical antipsychotic agents for treatment of insomnia Mental Health Clinician, March 2014^
  134. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia Behavioural Brain Research, March 2021^
  135. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis The Lancet. Psychiatry, January 2020^
  136. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update Journal of Psychopharmacology, August 2019^
  137. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Journal of Clinical Oncology, October 2017^
  138. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults The Cochrane Database of Systematic Reviews, September 2018^
  139. Getting it right the first time: recent progress in optimizing antiemetic usage Supportive Care in Cancer, March 2018^
  140. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Supportive Care in Cancer, June 2013^
  141. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy International Journal of Clinical Oncology, April 2018^
  142. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design Schizophrenia Research, May 2003^
  143. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis The American Journal of Psychiatry, May 2006^